BIONIC EYE TRIAL RESULTS SHOW SUBSTANTIAL VISION IMPROVEMENTS OVER TWO AND A HALF YEARS Blind participants with retinitis pigmentosa able to locate doorways, avoid obstacles
SEGMENT
Filmed in Melbourne and Sydney | February 2025
Released on Retinitis Pigmentosa Awareness Month
INTERVIEWED
Professor James Fallon,
Chief Technology Officer Bionics Institute &
Head of the Medical Bionics Department, University of Melbourne
Associate Professor Penelope Allen,
Head of Bionic Eye Project & Principal Investigator,
Centre for Eye Research Australia (CERA) &
Vitreoretinal Surgeon,
Royal Victorian Eye and Ear Hospital
Dr Ash Attia
Chief Executive Officer & Managing Director
Bionic Vision Technologies
Results of the first clinical trial of Australia’s ‘second generation’ bionic eye have demonstrated ‘substantial improvement’ in four participants’ functional vision, daily activities and quality of life over a period of more than two and a half years.
Detailed outcomes from the trial, led by the Centre for Eye Research Australia, Bionics Institute, University of Melbourne and Royal Victorian Eye and Ear Hospital, were published in Ophthalmology Science.
The findings add to interim results which showed that the second-generation bionic eye developed by Australian company Bionic Vision Technologies provided rapid improvements for four patients with blindness caused the genetic eye condition retinitis pigmentosa.
Retinitis pigmentosa is an inherited retinal disease which affects about two million people worldwide and is one of the leading causes of vision loss in working-age people.
The bionic eye comprises an electrode array, designed by the Bionics Institute and the Centre for Eye Research Australia, that is surgically implanted behind the eye. The electrode receives signals from a video camera mounted on glasses, which stimulate the patient’s retina.
Credit: Retinitis pigmentosa fact sheet from Retina Australia
-
Diary of a Paramedic in a primary health care clinic
Alecka Miles is a lecturer at Edith Cowan University and works as a paramedic in a multidisciplinary team at Dianella Family Medical Centre in Metropolitan Perth, Western Australia.
Community paramedic roles have a history in Australia, dating back to 2007 in New South Wales and followed by similar initiatives in South Australia and New Zealand. Alecka’s position emerged after she sought to evaluate how paramedics could integrate into general practice, ultimately leading to a job offer post-COVID lockdown in 2020. Her skills, particularly in cannulation, proved valuable as healthcare shifted towards primary care.
-
Clinical trial site in primary care setting open for novel therapies in psychiatry
Over the past decade, Paratus has been involved in over 200 clinical trials across 4 clinical site locations. Now a fifth site, the newly opened Melbourne site will cater to both primary care and psychiatry, specifically designed for psychedelic studies.
The new Melbourne site will be a focused on primary care studies specifically expanding access to psychiatric research, a growing area of unmet need. Australian Health Journal met with 3 recent hires brought in to support clinical trials across the organisation and in psychiatry in Melbourne.
-
Inaugural report into Australasian Paramedicine Workforce Survey report to aid workforce planning
In a milestone for paramedicine, the Australasian College of Paramedicine earlier this year released the first report of a landmark three-year study identifying and exploring trends that affect the Australasian paramedicine workforce.
The inaugural Australasian Paramedicine Workforce Survey report 2023-24 explores the demographic, career trajectory, work motivations and conditions for those working in clinical, management and educational capacities within the paramedicine workforce of Australia and Aotearoa New Zealand.
